|
1
|
Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1. NPJ Precis Oncol 2021; 5:20. [PMID: 33742100 PMCID: PMC7979705 DOI: 10.1038/s41698-021-00158-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 02/04/2021] [Indexed: 02/07/2023] Open
Abstract
E74-like ETS transcription factor 5 (ELF5) is involved in a wide spectrum of biological processes, e.g., mammogenesis and tumor progression. We have identified a list of p300-interacting proteins in human breast cancer cells. Among these, ELF5 was found to interact with p300 via acetylation, and the potential acetylation sites were identified as K130, K134, K143, K197, K228, and K245. Furthermore, an ELF5-specific deacetylase, SIRT6, was also identified. Acetylation of ELF5 promoted its ubiquitination and degradation, but was also essential for its antiproliferative effect against breast cancer, as overexpression of wild-type ELF5 and sustained acetylation-mimicking ELF5 mutant could inhibit the expression of its target gene CCND1. Taken together, the results demonstrated a novel regulation of ELF5 as well as shedding light on its important role in modulation of breast cancer progression.
Collapse
|
|
2
|
Yang X, Wu W, Peng M, Shen Q, Feng J, Lai W, Zhu H, Tu C, Quan X, Chen Y, Qin L, Li D, He L, Zhang Y. Identity-by-Descent Analysis Reveals Susceptibility Loci for Severe Acne in Chinese Han Cohort. J Invest Dermatol 2019; 139:2049-2051.e20. [PMID: 30922884 DOI: 10.1016/j.jid.2019.03.1132] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Revised: 02/20/2019] [Accepted: 03/05/2019] [Indexed: 10/27/2022]
Affiliation(s)
- Xingyan Yang
- State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, School of Life Sciences, Yunnan University, Kunming, China
| | - Wenjuan Wu
- Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Institute of Dermatology and Venereology of Yunnan Province, Kunming, China
| | - Minsheng Peng
- State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China; Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, China; KIZ/CUHK Joint Laboratory of Bio-Resources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China
| | - Quankuan Shen
- State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China; Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, China
| | - Jiaqi Feng
- Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Institute of Dermatology and Venereology of Yunnan Province, Kunming, China
| | - Wei Lai
- Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Huilan Zhu
- Guangzhou Institute of Dermatology, Guangzhou, China
| | - Caixia Tu
- Department of Dermatology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
| | - Xiaorong Quan
- Guilin Skin Disease Prevention and Treatment Hospital, Guilin, China
| | - Yihong Chen
- Department of Dermatology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China
| | - Lanying Qin
- Department of Dermatology, Cangzhou People's Hospital, Cangzhou, China
| | - Donglin Li
- Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Institute of Dermatology and Venereology of Yunnan Province, Kunming, China
| | - Li He
- Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Institute of Dermatology and Venereology of Yunnan Province, Kunming, China.
| | - Yaping Zhang
- State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, School of Life Sciences, Yunnan University, Kunming, China; State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China; Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, China; KIZ/CUHK Joint Laboratory of Bio-Resources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
| |
Collapse
|
|
3
|
Chan JM, Darke AK, Penney KL, Tangen CM, Goodman PJ, Lee GSM, Sun T, Peisch S, Tinianow AM, Rae JM, Klein EA, Thompson IM, Kantoff PW, Mucci LA. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev 2016; 25:1050-1058. [PMID: 27197287 DOI: 10.1158/1055-9965.epi-16-0104] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 04/12/2016] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Epidemiologic studies and secondary analyses of randomized trials supported the hypothesis that selenium and vitamin E lower prostate cancer risk. However, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed no benefit of either supplement. Genetic variants involved in selenium or vitamin E metabolism or transport may underlie the complex associations of selenium and vitamin E. METHODS We undertook a case-cohort study of SELECT participants randomized to placebo, selenium, or vitamin E. The subcohort included 1,434 men; our primary outcome was high-grade prostate cancer (N = 278 cases, Gleason 7 or higher cancer). We used weighted Cox regression to examine the association between SNPs and high-grade prostate cancer risk. To assess effect modification, we created interaction terms between randomization arm and genotype and calculated log likelihood statistics. RESULTS We noted statistically significant (P < 0.05) interactions between selenium assignment, SNPs in CAT, SOD2, PRDX6, SOD3, and TXNRD2, and high-grade prostate cancer risk. Statistically significant SNPs that modified the association of vitamin E assignment and high-grade prostate cancer included SEC14L2, SOD1, and TTPA In the placebo arm, several SNPs, hypothesized to interact with supplement assignment and risk of high-grade prostate cancer, were also directly associated with outcome. CONCLUSION Variants in selenium and vitamin E metabolism/transport genes may influence risk of overall and high-grade prostate cancer, and may modify an individual man's response to vitamin E or selenium supplementation with regards to these risks. IMPACT The effect of selenium or vitamin E supplementation on high-grade prostate cancer risk may vary by genotype. Cancer Epidemiol Biomarkers Prev; 25(7); 1050-8. ©2016 AACR.
Collapse
Affiliation(s)
- June M Chan
- Departments Of Epidemiology & Biostatistics and Urology, University of CA San Francisco
| | - Amy K Darke
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Kathryn L Penney
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston MA.,Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | - Catherine M Tangen
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Phyllis J Goodman
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Gwo-Shu Mary Lee
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA
| | - Tong Sun
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA
| | - Sam Peisch
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | - Alex M Tinianow
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston MA
| | - James M Rae
- Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Cancer Center, Michigan
| | - Eric A Klein
- Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH
| | - Ian M Thompson
- The Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - Philip W Kantoff
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA.,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Lorelei A Mucci
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston MA.,Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| |
Collapse
|